Nurix Q1 2022 Earnings Report
Key Takeaways
Nurix Therapeutics reported collaboration revenue of $9.6 million for the first quarter ended February 28, 2022. The company's net loss was $42.5 million, or ($0.95) per share. As of February 28, 2022, Nurix had cash, cash equivalents and investments of $385.7 million.
Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix’s drug-enhanced tumor infiltrating lymphocyte (TIL) program
Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607
Reported strong financial position with $385.7 million in cash and investments as of February 28, 2022
Achieved research milestones under its collaboration with Gilead and Sanofi
Nurix
Nurix
Nurix Revenue by Segment
Forward Guidance
Expected timing of events throughout the press release are based on calendar year quarters.